<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_BGU_Israel_Part_Collection skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:BGU Israel/Part Collection</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>OriginALS</TITLE></P><TITLE>OriginALS</TITLE><DIV class="topnav" id="myTopnav"><A href="https://2018.igem.org/Team:BGU_Israel" id="brand-img"> </A><DIV id="topnav-right"><A href="https://2018.igem.org/Team:BGU_Israel">Home</A><DIV class="dropdown"><BUTTON class="dropbtn">Project
      </BUTTON><DIV class="dropdown-content"><A href="https://2018.igem.org/Team:BGU_Israel/Description	">Description</A><A href="https://2018.igem.org/Team:BGU_Israel/Design">Design</A><A href="https://2018.igem.org/Team:BGU_Israel/Experiments">Experiments</A><A href="https://2018.igem.org/Team:BGU_Israel/Results">Results</A><A href="https://2018.igem.org/Team:BGU_Israel/Demonstrate">Demonstrate</A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtn">Lab
      </BUTTON><DIV class="dropdown-content"><A href="https://2018.igem.org/Team:BGU_Israel/Notebook">Notebook</A><A href="https://2018.igem.org/Team:BGU_Israel/Protocols">Protocols</A><A href="https://2018.igem.org/Team:BGU_Israel/InterLab">InterLab</A><A href="https://2018.igem.org/Team:BGU_Israel/Safety">Safety</A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtn">Team
      </BUTTON><DIV class="dropdown-content"><A href="https://2018.igem.org/Team:BGU_Israel/Team">Members</A><A href="https://2018.igem.org/Team:BGU_Israel/Collaborations">Collaborations</A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtn">Parts
      </BUTTON><DIV class="dropdown-content"><A href="https://2018.igem.org/Team:BGU_Israel/Parts">Overview</A><A href="https://2018.igem.org/Team:BGU_Israel/Basic_Part">Basic Parts</A><A href="https://2018.igem.org/Team:BGU_Israel/Part_Collection">Collection</A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtn">Human Practices
      </BUTTON><DIV class="dropdown-content"><A href="https://2018.igem.org/Team:BGU_Israel/Human_Practices">Integrated Human Practices</A><A href="https://2018.igem.org/Team:BGU_Israel/ALSConference">ALS Conference</A><A href="https://2018.igem.org/Team:BGU_Israel/Public_Engagement">Public Engagement</A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtn">Acknowledgements
      </BUTTON><DIV class="dropdown-content"><A href="https://2018.igem.org/Team:BGU_Israel/Attributions">Attributions</A><A href="https://2018.igem.org/Team:BGU_Israel/Sponsors">Sponsors</A></DIV></DIV><A href="javascript:void(0);" style="font-size:15px; " class="icon" onclick="myFunction()">☰</A></DIV></DIV><HEADER style="background-image:url('https://static.igem.org/mediawiki/2018/f/fd/T--BGU_Israel--green_subhead.png')!important;" class="sub-page-header text-center"><DIV class="container my-auto"><H1 class="animated fadeInUp">Part Collection</H1></DIV></HEADER><SECTION><DIV class="bg-dark text-center sub-nav"><DIV class="container"><H1 class="animated fadeInRight">Choose Your Collection</H1><DIV class="row animated fadeInLeft"><A href="#OriginALS" class="btn btn-info" role="button">OriginALS</A><A href="#Astrocyte" class="btn btn-info" role="button">Astrocyte</A><A href="#Microglia" class="btn btn-info" role="button">Microglia</A><A href="#CRISPR" class="btn btn-info" role="button">CRISPR</A><A href="#Promoters" class="btn btn-info" role="button">Promoters</A></DIV></DIV></DIV><DIV id="OriginALS" class="bg-white"><DIV class="container text-center"><H1>OriginALS collection</H1><DIV class="row"><DIV class="col-sm-8 col-sm-offset-2"><P class="justified" style="margin:20px;">
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no available treatment. The BGU-IGEM team aims to develop a system that will ultimately prolong survival of ALS patients by targeting microglia and reactive astrocytes, which are both non-neuronal cells that directly contribute to motor neuronal damage.
The &quot;OriginALS&quot; collection was designed to fulfill our therapeutic approach:</P><OL><LI>Inhibition of toxic pro-inflammatory cytokines secretion in microglia cells.</LI><LI>Promoting intrinsic apoptotic signal in reactive astrocytes and preventing their toxic effect on motor neurons.</LI></OL><TABLE><TBODY><TR><TD width="282"><P>Short description</P></TD><TD width="102"><P>NickName</P></TD><TD width="217"><P>Part link</P></TD></TR><TR><TD width="282"><P>Tissue inhibitor of metalloproteinases-1 promoter (pTIMP1)</P></TD><TD width="102"><P>pTIMP1</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538005">BBa_K2538005</A></P></TD></TR><TR><TD width="282"><P>gRNA#1 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6 g1</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538000">BBa_K2538000</A></P></TD></TR><TR><TD width="282"><P>gRNA#2 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6-g2</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538001">BBa_K2538001</A></P></TD></TR><TR><TD width="282"><P>gRNA#5 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6-g5</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538002">BBa_K2538002</A></P></TD></TR><TR><TD width="282"><P>gRNA#6 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6-g6</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538003">BBa_K2538003</A></P></TD></TR><TR><TD width="282"><P>Microglia specific promoter pF4/80</P></TD><TD width="102"><P>pF4/80</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538006">BBa_K2538006</A></P></TD></TR><TR><TD width="282"><P>Six Transmembrane Epithelial Antigen of Prostate 4 promoter (pSTEAP4) with a point mutation</P></TD><TD width="102"><P>pSTEAP4 +mut</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538007">BBa_K2538007</A></P></TD></TR><TR><TD width="282"><P>Six Transmembrane Epithelial Antigen of Prostate 4 promoter (pSTEAP4)</P></TD><TD width="102"><P>pSTEAP4</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538008">BBa_K2538008</A></P></TD></TR><TR><TD width="282"><P>Synthetic minimal adenovirus major late promoter (pMLPm)</P></TD><TD width="102"><P>pMLP</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538009">BBa_K2538009</A></P></TD></TR><TR><TD width="282"><P>Ribozyme flanked gRNA for SadCas9 VP64 targeting synthetic activation promoter pMLPm</P></TD><TD width="102"><P>RGR gRNA</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538010">BBa_K2538010</A></P></TD></TR><TR><TD width="282"><P>pSTEAP4 RGR gRNA (composite part)</P></TD><TD width="102"><P>pSTEAP4 RGR gRNA</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538011">BBa_K2538011</A></P></TD></TR></TBODY></TABLE><P class="justified" style="margin:20px;">Using modified genome editing technique, we built a system that specifically targets toxic astrocytes and prevents the formation of new ones which hopefully will slow down the progression of the disease. As the reactivity of microglia and astrocytes is common to many neurodegenerative diseases, our novel approach could be expanded to other neurodegenerative diseases.
In this unique collection you can find our specific promoters and gRNA.</P></DIV></DIV></DIV></DIV><DIV id="Astrocyte" class="bg-grey"><DIV class="container text-center"><H1>Astrocyte collection</H1><DIV class="row"><DIV class="col-sm-8 col-sm-offset-2 text-center"><P class="justified" style="margin:20px;">
In the astrocytes pathway, we aim to identify and eliminate only reactive astrocytes. In order to identify the reactive astrocytes, we will use the promoters of the distinguishing markers, pSTEAP4 and pTIMP1. The TIMP1 and STEAP4 genes have high levels of expression specifically in A1 reactive astrocyte when compared to other cells in the central nervous system.
pTIMP1 promoter regulates the expression of dCas9 fused to VP64 transcription factor.
pSTEAP4 promoter regulates the expression of gRNA which its spacer is complementary to three different loci in the synthetic minimal adenovirus major late promoter (pMLPm).

The pMLPm promoter will be active only under the condition that gRNA-dCas9-VP64 complex promotes downstream transcription. When the transcription factor VP64 (an engineered tetramer of the herpes simplex VP16 transcriptional activator domain) is fused to dCas9 enzyme it can be guided to a specific location in the genome, in this manner we can exploit it to promote downstream translation.</P><P>Short description</P><P>NickName</P><P>Part link</P><P>Tissue inhibitor of metalloproteinases-1 promoter (pTIMP1)</P><P>pTIMP1</P><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538005">BBa_K2538005</A></P><P>Six Transmembrane Epithelial Antigen of Prostate 4 promoter (pSTEAP4) with a point mutation</P><P>pSTEAP4 +mut</P><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538007">BBa_K2538007</A></P><P>Six Transmembrane Epithelial Antigen of Prostate 4 promoter (pSTEAP4)</P><P>pSTEAP4</P><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538008">BBa_K2538008</A></P><P>Synthetic minimal adenovirus major late promoter (pMLPm)</P><P>pMLP</P><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538009">BBa_K2538009</A></P><P>Ribozyme flanked gRNA for SadCas9 VP64 targeting synthetic activation promoter pMLPm</P><P>RGR gRNA</P><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538010">BBa_K2538010</A></P><P>pSTEAP4 RGR gRNA (composite part)</P><P>pSTEAP4 RGR gRNA</P><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538011">BBa_K2538011</A></P><P class="justified" style="margin:20px;">
The gRNA-dCas9-VP64 complex will target the synthetic minimal adenovirus major late promoter (pMLPm) and promote the expression of exogenous reverse caspase3, that in contrast to the endogenous caspas3 will be activated after transcription due to its autocatalytic processing, meaning this enzyme will trigger an apoptotic signal that will lead to apoptotic death (caspase3 is responsible for chromatin condensation and DNA fragmentation).

By reducing the amount of reactive astrocytes we will prevent motor neuron death and prolong ALS patient survival.
In this collection you can find our specific A1 reactive astrocyte promoters (pSTEAP4 and pTIMP1), pMLPm promoter and gRNA targeting pMLPm promoter for activation via dCas9 VP64 system.</P></DIV></DIV></DIV></DIV><DIV id="Microglia" class="bg-white"><DIV class="container text-center"><H1>Microglia collection</H1><DIV class="row"><DIV class="col-sm-8 col-sm-offset-2"><P class="justified" style="margin:20px;">
In the microglia pathway, we will knockout the IKKβ gene in microglia cells, using the CRISPR-Cas9 system delivered by AAV6 virus that targets microglia cells. The IKKβ gene is transcribed and translated into a kinase which has a role as an activator upstream to the NFkB complex assembly. Therefore, the knockout will decrease the neuro-inflammation transduced by classical NFkB signal.
Targeting specifically microglia cells, we chose to combine the pF4/80 promoter, which is a known macrophage marker, with AAV6 viral vector.
</P><TABLE><TBODY><TR><TD width="282"><P>Short description</P></TD><TD width="102"><P>NickName</P></TD><TD width="217"><P>Part link</P></TD></TR><TR><TD width="282"><P>gRNA#1 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6 g1</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538000">BBa_K2538000</A></P></TD></TR><TR><TD width="282"><P>gRNA#2 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6-g2</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538001">BBa_K2538001</A></P></TD></TR><TR><TD width="282"><P>gRNA#5 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6-g5</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538002">BBa_K2538002</A></P></TD></TR><TR><TD width="282"><P>gRNA#6 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6-g6</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538003">BBa_K2538003</A></P></TD></TR><TR><TD width="282"><P>Microglia specific promoter pF4/80</P></TD><TD width="102"><P>pF4/80</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538006">BBa_K2538006</A></P></TD></TR></TBODY></TABLE><P class="justified" style="margin:20px;">
The pF4/80 promoter will be responsible for the expression of the Cas9 protein, while the U6 promoter, which is a non-specific promoter, is responsible for the expression of the IKKβ guide RNA sequence.
Our CRISPR Cas9 system will target and knock out the IKKβ gene, resulting in the inhibition of pro-inflammatory cytokines synthesis and secretion and thus reduce the formation of new reactive astrocytes in the system.
In this collection you can find pF4/80 promoter and 4 different gRNA targeting the IKKβ for gene knockout via CRISPR Cas9 system.</P></DIV></DIV></DIV></DIV><DIV id="CRISPR" class="bg-grey"><DIV class="container text-center"><H1 style="text-transform: none!important;">CRISPR gRNA Collection</H1><DIV class="row"><DIV class="col-sm-8 col-sm-offset-2 text-center"><P class="justified" style="margin:20px;">
Guide RNA (gRNA) is a hundred base-long molecule, it includes a scaffold sequence which has a unique two dimensional structure necessary for Cas9 binding and a spacer sequence designed to target a specific location in the genome.

In this collection you can find 4 different gRNA targeting the IKKβ for gene knockout via CRISPR Cas9 system, and gRNA for the synthetic minimal adenovirus major late promoter (pMLPm) activation via dCas9 VP64 system. 
</P><TABLE><TBODY><TR><TD width="282"><P>Short description</P></TD><TD width="102"><P>NickName</P></TD><TD width="217"><P>Part link</P></TD></TR><TR><TD width="282"><P>gRNA#1 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6 g1</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538000">BBa_K2538000</A></P></TD></TR><TR><TD width="282"><P>gRNA#2 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6-g2</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538001">BBa_K2538001</A></P></TD></TR><TR><TD width="282"><P>gRNA#5 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6-g5</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538002">BBa_K2538002</A></P></TD></TR><TR><TD width="282"><P>gRNA#6 for SaCas9 targeting of IKKβ  under U6 promoter</P></TD><TD width="102"><P>U6-g6</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538003">BBa_K2538003</A></P></TD></TR><TR><TD width="282"><P>Ribozyme flanked gRNA for SadCas9 VP64 targeting synthetic activation promoter pMLPm</P></TD><TD width="102"><P>RGR gRNA</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538010">BBa_K2538010</A></P></TD></TR></TBODY></TABLE><P> </P><P class="justified" style="margin:20px;">
In a future therapeutic approach, it is envisioned that all gRNAs variants will be used together in as a cocktail of viruses in order to achieve higher CRISPR Cas9 efficiency.</P></DIV></DIV></DIV></DIV><DIV id="Promoters" class="bg-white"><DIV class="container text-center"><H1>Promoters collection</H1><DIV class="row"><DIV class="col-sm-8 col-sm-offset-2"><P class="justified" style="margin:20px;">
In this collection you can find all the promoters we used in our project targeting different types of cells. 
pTIMP1 and pSTEAP4 promoters were chosen to target A1 reactive astrocyte, since the TIMP1 and STEAP4 genes have high levels of expression specifically in those cells when compared to other cells in the central nervous system. pF4/80 were chosen to target microglia cells. 

</P><TABLE><TBODY><TR><TD width="282"><P>Short description</P></TD><TD width="102"><P>NickName</P></TD><TD width="217"><P>Part link</P></TD></TR><TR><TD width="282"><P>Tissue inhibitor of metalloproteinases-1 promoter (pTIMP1)</P></TD><TD width="102"><P>pTIMP1</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538005">BBa_K2538005</A></P></TD></TR><TR><TD width="282"><P>Microglia specific promoter pF4/80</P></TD><TD width="102"><P>pF4/80</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538006">BBa_K2538006</A></P></TD></TR><TR><TD width="282"><P>Six Transmembrane Epithelial Antigen of Prostate 4 promoter (pSTEAP4) with a point mutation</P></TD><TD width="102"><P>pSTEAP4 +mut</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538007">BBa_K2538007</A></P></TD></TR><TR><TD width="282"><P>Six Transmembrane Epithelial Antigen of Prostate 4 promoter (pSTEAP4)</P></TD><TD width="102"><P>pSTEAP4</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538008">BBa_K2538008</A></P></TD></TR><TR><TD width="282"><P>Synthetic minimal adenovirus major late promoter (pMLPm)</P></TD><TD width="102"><P>pMLP</P></TD><TD width="217"><P><A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2538009">BBa_K2538009</A></P></TD></TR></TBODY></TABLE><P> </P></DIV></DIV></DIV></DIV><DIV id="myModal" class="modal"><SPAN class="close" onclick="modal.style.display = 'none'">×</SPAN></DIV><TITLE>OriginALS</TITLE><FOOTER style="margin-bottom:-10px!important;margin-top:-10px!important;"><DIV class="container my-auto"><DIV class="row"><DIV class="col-md-4"><H3 style="color:white!important;">About Us</H3><P style="color:white!important;text-align: justify!important;">The BGU-iGEM team “OriginALS” hopes to develop an innovative therapeutic approach to prolong the life expectancy of ALS patients, using Synthetic Biology. We are dedicated to promoting ALS awareness and research in Israel through public engagement and educational activities.</P></DIV><DIV class="col-md-4"><UL class="footer-list"><H3>Keep in Touch</H3><LI class="footer-list-item"> @iGEMBGU</LI><LI class="footer-list-item">@igem_2018_bgu</LI><LI class="footer-list-item"> @originalsbgu</LI><LI class="footer-list-item"> originalsbgu@gmail.com</LI></UL></DIV><DIV class="col-md-4"><UL class="footer-list"><H3>Address</H3><LI class="footer-list-item">Ben-Gurion University of the Negev
Ben Gurion 1, Beer Sheva 8410501, Israel</LI></UL></DIV></DIV></DIV></FOOTER></SECTION></DIV></DIV></DIV></DIV></DIV></BODY></HTML>